BIOA trades 330.9% below Wall Street's consensus target of $34.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BIOA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, BioAge Labs Inc. (BIOA) has a Wall Street consensus price target of $34.00, based on estimates from 6 covering analysts. With the stock currently trading at $7.89, this represents a potential upside of +330.9%. The company has a market capitalization of $297M.
Analyst price targets range from a low of $21.00 to a high of $50.00, representing a 85% spread in expectations. The median target of $32.50 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BIOA trades at a trailing P/E of -3.5x. Analysts expect EPS to grow -15.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 KYMRKymera Therapeutics, Inc. | $9.5B | $115.47 | $136.75 | +18.4% | Buy | — | 27 |
 RVMDRevolution Medicines, Inc. | $40.6B | $190.74 | $247.00 | +29.5% | Buy | — | 24 |
 LNTHLantheus Holdings, Inc. | $6.5B | $99.97 | $104.48 | +4.5% | Buy | 18.5x | 19 |
 RYTMRhythm Pharmaceuticals, Inc. | $6.7B | $98.24 | $143.83 | +46.4% | Buy | — | 22 |
 VNDAVanda Pharmaceuticals Inc. | $303M | $5.04 | $21.00 | +316.7% | Buy | — | 19 |
 NUVLNuvalent, Inc. | $9.1B | $123.96 | $127.32 | +2.7% | Hold | — | 19 |
 IMVTImmunovant, Inc. | $7.1B | $34.54 | $40.00 | +15.8% | Buy | — | 23 |
 ARDXArdelyx, Inc. | $860M | $3.48 | $13.00 | +273.6% | Buy | — | 16 |
 LLYEli Lilly and Company | $1.1T | $1152.70 | $1343.07 | +16.5% | Buy | 31.7x | 45 |
 NVONovo Nordisk A/S | $169.5B | $38.17 | $44.67 | +17.0% | Buy | 1.7x | 39 |
Quick answers to the most common questions about buying BIOA stock.
The consensus Wall Street price target for BIOA is $34, representing 330.9% upside from the current price of $7.89. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BIOA has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $34 implies 330.9% upside from current levels.
BIOA's current price is $7.89 with a consensus target of $34 (330.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $50 for BIOA, while the most conservative target is $21. The consensus of $34 represents the median expectation. These targets typically reflect 12-month expectations.
BIOA is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BIOA stock forecast based on 6 Wall Street analysts shows a consensus price target of $34, with estimates ranging from $21 (bear case) to $50 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on BIOA, with a "Buy" consensus rating and $34 price target (330.9% upside). 5 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BIOA analyst price targets range from $21 to $50, a 85% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $34 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.